Devroe Eric, Chief Operating Officer of Acrivon Therapeutics ($ACRV), made one open market purchase of shares worth $17,218 in the last year, with the most recent on January 13, 2026. He ranks 3,956th out of 4,983 insiders for purchase amounts, below the average of $1.46 million across 3.29 transactions. Devroe Eric reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 1, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | A | Stock Option (Right to Buy) | 186728 | $0.00 | 186,728.0000 | 38,560,464 | 9999.99% | 0.48% |
| Feb. 14, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | F | Common Stock | 723 | $1.63 | 74,585.0000 | 38,560,464 | 0.96% | 0.00% |
| Jan. 13, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | P | Common Stock | 10000 | $1.72 | 75,308.0000 | 38,560,464 | 15.31% | 0.03% |
| Nov. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | F | Common Stock | 613 | $2.24 | 65,308.0000 | 38,560,464 | 0.93% | 0.00% |
| Aug. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | F | Common Stock | 613 | $1.39 | 65,921.0000 | 33,791,817 | 0.92% | 0.00% |
| May 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | F | Common Stock | 613 | $1.14 | 66,534.0000 | 33,791,817 | 0.91% | 0.00% |
| March 1, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | A | Stock Option (Right to Buy) | 140540 | $0.00 | 140,540.0000 | 33,791,817 | 9999.99% | 0.42% |
| Feb. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | F | Common Stock | 724 | $5.42 | 67,147.0000 | 33,791,817 | 1.07% | 0.00% |
| March 1, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | A | Stock Option (Right to Buy) | 90090 | $0.00 | 90,090.0000 | 22,078,190 | 9999.99% | 0.41% |
| Nov. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | F | Common Stock | 613 | $7.92 | 67,871.0000 | 38,105,131 | 0.90% | 0.00% |
| Aug. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | F | Common Stock | 613 | $7.02 | 68,484.0000 | 22,078,190 | 0.89% | 0.00% |
| May 17, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | M | Stock Option (Right to Buy) | 10000 | $0.00 | 86,615.0000 | 22,078,190 | 10.35% | 0.05% |
| May 17, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | M | Common Stock | 10000 | $1.04 | 69,097.0000 | 22,078,190 | 16.92% | 0.05% |
| May 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | F | Common Stock | 613 | $8.36 | 59,097.0000 | 22,078,190 | 1.03% | 0.00% |
| Feb. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | F | Common Stock | 723 | $3.40 | 59,710.0000 | 22,078,190 | 1.20% | 0.00% |
| Nov. 14, 2023 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | F | Common Stock | 2450 | $5.08 | 60,433.0000 | 0 | 3.90% | 0.00% |
| June 5, 2023 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | M | Stock Option (Right to Buy) | 9225 | $0.00 | 96,615.0000 | 0 | 8.72% | 0.00% |
| June 5, 2023 | Acrivon Therapeutics, Inc. | $ACRV | Devroe Eric | Chief Operating Officer | M | Common Stock | 9225 | $1.04 | 62,883.0000 | 0 | 17.19% | 0.00% |